Relmada Therapeutics to Participate in Jefferies Healthcare Conference
Relmada Therapeutics said it will participate in the Jefferies Global Healthcare Conference in London.
Related stories
Advantage Solutions Reports Q3 Results, Announces Restructuring
Advantage Solutions reported revenue of $913.7 million and a net loss of $25.1 million for the quarter ended September 30, 2026. Its restructuring is expected to deliver about $25
M impact | EQUITY | Nov 04, 2026, 02:15 PM UTC
InnovAge Reports Fiscal Q1 2027 Revenue of $264.8 Million
Revenue rose 12.1% year over year and income before taxes increased 153.1% to $20.0 million. Diluted EPS was $0.14 versus analyst expectations of $0.09. Fiscal 2027 revenue guidanc
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Solid Power Reports Q3 2026 Results, Cuts Cash Investment Outlook
Solid Power reported third-quarter revenue and grant income of $1.2 million and a net loss of $24.4 million, or $0.11 per share. It lowered its 2026 cash investment outlook to $75
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Shoals Technologies Reports Q3 Revenue of $195.3 Million, Raises 2026 Outlook
Revenue rose 43.8% year over year to $195.3 million, and adjusted EBITDA reached $39.8 million, above the company’s expected range. Shoals guided to fiscal 2026 revenue of $665 mil
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Taboola Reports Q3 Revenue of $462.3 Million, Issues Q4 Guidance
Taboola reported Q3 revenue of $462.3 million, below a FactSet estimate of $466.3 million. Adjusted EBITDA rose 16.1% to $56.0 million, and net income increased to $18.4 million fr
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Flowco Reports Third-Quarter 2026 Revenue of $258.6 Million
Flowco reported net income of $40.7 million, adjusted EBITDA of $103.9 million and free cash flow of $72.4 million. Diluted EPS was $0.40, above the FactSet consensus estimate of $
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC